Mazen ­čç║­čçŞ

Mazen uses molecular farming to create oral livestock vaccines.

Mazen

Total Raised
$13.0 million
Latest Round
Series A

Investors

AgFunder, Fall Line Capital.

Summary

Mazen is an animal health company developing novel biological vaccines and therapeutics to replace existing injectable vaccines. They have developed a vaccine platform that uses maize as a biofactory for the production of recombinant vaccines. This enables the delivery of oral vaccines in an edible form providing distinct advantages over injectables, topicals, and water-based orals.

Why we invested

  • Protein producers are facing a number of challenges with the current vaccination process (low efficacy rates, labor shortages, worker welfare, animal welfare, biosecurity) that support the quick adoption of shelf-stable, needleless oral vaccines. 
  • Mazen has an extraordinary management team of seasoned industry experts.
  • While Mazen is an animal health company first, they have the potential to become a platform for the production of all kinds of high-value recombinant proteins. 

 

 

Contact Mazen

info@mazenanimalhealth.com

 

 


Team

Jenny Filbey
Cofounder/CEO

Jenny previously founded New Perspectives, a consulting enterprise that provides business leadership, strategic planning, commercialization, business development, and licensing to small to midsize companies. Before that, she was a VP of business development at the pharmaceutical company Neos Therapeutics. Other roles include operations and logistics, business development, and senior scientist for companies like Orexo, Nektar Therapeutics, Nobex Corporation, and Hoechst. Jenny holds a PhD in Physical Chemistry from Virginia Tech.

John Howard
John Howard
Cofounder/CSO

John is the world leader in protein expression in maize grain. He has over 30 years of experience in directing biotechnology groups in research, regulatory, production, IP, and business development. John published the first demonstration of protection from a plant-produced oral vaccine in pigs. He is an author of over 100 publications and patents in biotech. John has a PhD in Biochemistry from the University of California, Riverside.